These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35207448)

  • 21. The bispecific B7H3xCD3 antibody CC-3 induces T cell immunity against bone and soft tissue sarcomas.
    Holzmayer SJ; Liebel K; Hagelstein I; Salih HR; Märklin M
    Front Immunol; 2024; 15():1391954. PubMed ID: 38765008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
    Loo D; Alderson RF; Chen FZ; Huang L; Zhang W; Gorlatov S; Burke S; Ciccarone V; Li H; Yang Y; Son T; Chen Y; Easton AN; Li JC; Rillema JR; Licea M; Fieger C; Liang TW; Mather JP; Koenig S; Stewart SJ; Johnson S; Bonvini E; Moore PA
    Clin Cancer Res; 2012 Jul; 18(14):3834-45. PubMed ID: 22615450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy.
    Frey G; Cugnetti APG; Liu H; Xing C; Wheeler C; Chang HW; Boyle WJ; Short JM
    MAbs; 2024; 16(1):2322562. PubMed ID: 38445633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody-Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models.
    Yamato M; Hasegawa J; Maejima T; Hattori C; Kumagai K; Watanabe A; Nishiya Y; Shibutani T; Aida T; Hayakawa I; Nakada T; Abe Y; Agatsuma T
    Mol Cancer Ther; 2022 Apr; 21(4):635-646. PubMed ID: 35149548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
    Scribner JA; Brown JG; Son T; Chiechi M; Li P; Sharma S; Li H; De Costa A; Li Y; Chen Y; Easton A; Yee-Toy NC; Chen FZ; Gorlatov S; Barat B; Huang L; Wolff CR; Hooley J; Hotaling TE; Gaynutdinov T; Ciccarone V; Tamura J; Koenig S; Moore PA; Bonvini E; Loo D
    Mol Cancer Ther; 2020 Nov; 19(11):2235-2244. PubMed ID: 32967924
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma.
    Zheng M; Yu L; Hu J; Zhang Z; Wang H; Lu D; Tang X; Huang J; Zhong K; Wang Z; Li Y; Guo G; Liu S; Tong A; Yang H
    Transl Oncol; 2020 May; 13(5):100770. PubMed ID: 32298986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma.
    Brignole C; Calarco E; Bensa V; Giusto E; Perri P; Ciampi E; Corrias MV; Astigiano S; Cilli M; Loo D; Bonvini E; Pastorino F; Ponzoni M
    J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37775116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
    Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
    Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NK-Cell-Mediated Targeting of Various Solid Tumors Using a B7-H3 Tri-Specific Killer Engager In Vitro and In Vivo.
    Vallera DA; Ferrone S; Kodal B; Hinderlie P; Bendzick L; Ettestad B; Hallstrom C; Zorko NA; Rao A; Fujioka N; Ryan CJ; Geller MA; Miller JS; Felices M
    Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32961861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3.
    Ahmed M; Cheng M; Zhao Q; Goldgur Y; Cheal SM; Guo HF; Larson SM; Cheung NK
    J Biol Chem; 2015 Dec; 290(50):30018-29. PubMed ID: 26487718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers.
    Birley K; Leboreiro-Babe C; Rota EM; Buschhaus M; Gavriil A; Vitali A; Alonso-Ferrero M; Hopwood L; Parienti L; Ferry G; Flutter B; Himoudi N; Chester K; Anderson J
    Mol Ther Oncolytics; 2022 Sep; 26():429-443. PubMed ID: 36159778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers.
    Wang N; Patel H; Schneider IC; Kai X; Varshney AK; Zhou L
    Antib Ther; 2021 Apr; 4(2):90-100. PubMed ID: 34169228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of hepatocellular carcinoma with a GPC3-targeted bispecific T cell engager.
    Bi Y; Jiang H; Wang P; Song B; Wang H; Kong X; Li Z
    Oncotarget; 2017 Aug; 8(32):52866-52876. PubMed ID: 28881778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.
    Yang M; Tang X; Zhang Z; Gu L; Wei H; Zhao S; Zhong K; Mu M; Huang C; Jiang C; Xu J; Guo G; Zhou L; Tong A
    Theranostics; 2020; 10(17):7622-7634. PubMed ID: 32685008
    [No Abstract]   [Full Text] [Related]  

  • 37. New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3.
    Koumprentziotis IA; Theocharopoulos C; Foteinou D; Angeli E; Anastasopoulou A; Gogas H; Ziogas DC
    Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
    Picarda E; Ohaegbulam KC; Zang X
    Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel Fc-enhanced humanized monoclonal antibody targeting B7-H3 suppresses the growth of ESCC.
    Wu H; Liu C; Yuan Q; Qiao Y; Ding Y; Duan L; Li W; Zhang M; Zhang X; Jiang Y; Lu J; Dong Z; Wang T; Liu K; Zhao J
    Oncoimmunology; 2023; 12(1):2282250. PubMed ID: 38126034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.